The eye and thyroid disease
نویسندگان
چکیده
منابع مشابه
Radioiodine and thyroid eye disease.
1 NHS Executive. The new NHS: a national framework for assessing performance. London: Department of Health, 1998. 2 Bindman A B, Grumbach K, Osmond D, Komarony M, Vranizan K, Lurie N, et al. Preventable hospitalisations and access to health care. JAMA 1995;274:305-11. 3 Reid FDA, Cook D, Majeed FA. Variation in hospital admission rates between general practices: cross sectional study. BMJ 1999;...
متن کاملThyroid eye disease.
Most patients receive conservative treatment — lubrication of the eye to reduce symptoms related to disturbance of the tear film. About 5% of patients will need more aggressive therapy (e.g., systemic corticosteroids, orbital radiation, surgical removal of orbital walls) to prevent vision loss caused by either compression of the optic nerve by enlarging extraocular muscles or corneal ulceration...
متن کاملThyroid Eye Disease
Treatment ........................................................... 16 Introduction to treatment ................................ 16 Management of systemic hyperthyroidism...... 17 Overview of treatment options ....................... 20 o Corticosteroids .......................................... 20 o Orbital radiotherapy .................................. 20 o Selenium ..................
متن کاملThyroid Eye Disease
Management is challenging and requires a team approach. Medical management is only available in the active, early phase. When the disease becomes inactive (no acute inflammation), surgery is the only option. TED is sight-threatening in up to 5% of patients, although most cases are mild and self-limiting. [1]See also separate articles Thyroid Function Tests, Hyperthyroidism, Hyperthyroidism in P...
متن کاملRituximab for thyroid eye disease.
PURPOSE To assess the efficacy and safety of rituximab-mediated B-lymphocyte depletion as treatment for thyroid eye disease (TED). METHODS Prospective, open-label, interventional clinical trial evaluating 12 patients with TED and Clinical Activity Scores (CAS) (VISA [vision, inflammation, strabismus and appearance/exposure] classification) of 4 or greater followed for 1 year after rituximab (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Ophthalmology
سال: 2008
ISSN: 1040-8738
DOI: 10.1097/icu.0b013e3283131557